Your browser doesn't support javascript.
loading
Metachronous Osteosarcoma, A Differential Diagnosis to be Considered in Children With Osteosarcoma: A Review of Literature and a Case From Our Center.
Gotta, Jennifer; Bochennek, Konrad; Klingebiel, Thomas; Bielack, Stefan; Wild, Peter J; Demes, Melanie C; Gradhand, Elise.
Afiliación
  • Gotta J; Dr Senckenberg Institute of Pathology.
  • Bochennek K; Department for Children and Adolescents Medicine, University Hospital Frankfurt, Frankfurt am Main.
  • Klingebiel T; Department for Children and Adolescents Medicine, University Hospital Frankfurt, Frankfurt am Main.
  • Bielack S; Center for Pediatric, Adolescent and Women's Medicine, Olgahospital, Department of Pediatrics 5 (Oncology, Hematology, Immunology), Klinikum Stuttgart, Stuttgart, Germany.
  • Wild PJ; Dr Senckenberg Institute of Pathology.
  • Demes MC; Frankfurt Institute for Advanced Studies (FIAS).
  • Gradhand E; Wildlab, University Hospital MVZ GmbH, Frankfurt am Main.
J Pediatr Hematol Oncol ; 45(3): 105-110, 2023 04 01.
Article en En | MEDLINE | ID: mdl-36251795
ABSTRACT
Metachronous osteosarcomas (MOS) are currently defined as tumors that arise in a way and site unusual for typical metastasis. In this article, we reviewed the recent literature on the occurrence of metachronous osteosarcoma and presented a case from our center. Our patient, a 10-year-old girl, presented with metachronous osteoblastic osteosarcoma of the left distal femur ∼5 years after the successful treatment for osteosarcoma of the right distal femur. Even after several relapses, complete remission (CR) was achieved after the first osteosarcoma and after the metachronous osteosarcoma. The literature research revealed that metachronous osteosarcoma occurs in 3.4 to 5.4% of osteosarcoma patients. The time interval between the diagnosis of the initial osteosarcoma and the metachronous tumor ranged from 0.2 to 14.3 years (median 2.5 y). MOS appears to have differences in localization and metastatic spread, as well as a different survival pattern compared with primary osteosarcoma and osteosarcoma recurrence. Survival (median 4.3 y, range 0 to 24.6 y) appears to be associated with the time interval to diagnosis of MOS. In particular, early MOS (<24 mo after primary diagnosis) seem to have a poorer prognosis. Therefore, the occurrence of MOS at oncological unusual sites should be considered as a differential diagnosis in osteosarcoma survivors.
Asunto(s)

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias Óseas / Osteosarcoma / Neoplasias Primarias Secundarias Tipo de estudio: Diagnostic_studies Límite: Child / Female / Humans Idioma: En Revista: J Pediatr Hematol Oncol Asunto de la revista: HEMATOLOGIA / NEOPLASIAS / PEDIATRIA Año: 2023 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias Óseas / Osteosarcoma / Neoplasias Primarias Secundarias Tipo de estudio: Diagnostic_studies Límite: Child / Female / Humans Idioma: En Revista: J Pediatr Hematol Oncol Asunto de la revista: HEMATOLOGIA / NEOPLASIAS / PEDIATRIA Año: 2023 Tipo del documento: Article